Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Sponsor: Massachusetts General Hospital
Summary
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.
Official title: 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) for Relapsed/Refractory B-cell Lymphoma Prior to CAR T-cell Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2024-01-14
Completion Date
2024-12-01
Last Updated
2026-10-15
Healthy Volunteers
No
Conditions
Interventions
Adaptive Bridging Radiation Therapy (ABRT)
Radiation Therapy
Locations (2)
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States